Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

References

• Owen C, Berinstein NL, Christofides A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233–e240. doi:10.3747/co.26.4345
   PubMed Web of Science ®Google Scholar
• Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171. doi:10.1186/s13045-017-0537-5
   PubMedGoogle Scholar
• McKay P, Leach M, Jackson B, et al. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182(1):46–62. doi:10.1111/bjh.15283
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778. doi:10.1016/S0140-6736(15)00667-4
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi:10.1056/NEJMoa1914347
   PubMed Web of Science ®Google Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71. doi:10.3324/haematol.2018.198812
   PubMed Web of Science ®Google Scholar
• McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684–688. doi:10.1111/bjh.16416
   PubMed Web of Science ®Google Scholar
• Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with ­mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–587. doi:10.1111/bjh.15567
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563. doi:10.1182/blood-2015-10-673145
   PubMed Web of Science ®Google Scholar
• Hess G, Dreyling M, Oberic L, et al. Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR‐2 retrospective chart review study. Br J Haematol. 2023;202(4):749–759. doi:10.1111/bjh.18519
   PubMed Web of Science ®Google Scholar
• Patel D, Grimson F, Mihaylova E, et al. Use of external comparators for health technology assessment submissions based on Single-Arm trials. Value Health. 2021;24(8):1118–1125. doi:10.1016/j.jval.2021.01.015
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2022;2022:JCO2102370.
   Google Scholar
• Hernán MA, Sauer BC, Hernández-Díaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–75. doi:10.1016/j.jclinepi.2016.04.014
   PubMed Web of Science ®Google Scholar
• Faria R, Hernandez Alava M, Manca A, et al. NICE DSU Technical Support Document 17: the use of observational data to inform estimates of treatment effectiveness for technology appraisal: methods for comparative individual patient data; 2015.
   Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016.
   Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657. doi:10.1136/bmj.l5657
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107. doi:10.1002/sim.3697
   PubMed Web of Science ®Google Scholar
• Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338(1):b2393–b2393. doi:10.1136/bmj.b2393
   PubMedGoogle Scholar
• Kang JDY, Schafer JL. Demystifying double robustness: a comparison of alternative strategies for estimating a population mean from incomplete data. Stat Sci. 2007;22(4):523–539.
   Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346. doi:10.1016/0197-2456(96)00075-x
   PubMedGoogle Scholar
• R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
   Google Scholar
• Dreyling M, Shah B, Wu JJ, et al. SA29 efficacy outcomes following treatment with bruton tyrosine kinase inhibitors (BTKI) for relapsed/refractory mantle cell lymphoma (R/R MCL): a literature-based meta-analysis. Value in Health. 2022;25(7):S609–S610. doi:10.1016/j.jval.2022.04.1695
   Web of Science ®Google Scholar
• Phillips TJ, Dickinson M, Morschhauser F, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Blood. 2022;140(Supplement 1):178–180. doi:10.1182/blood-2022-157777
   Google Scholar
• Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent BTK-Inhibitor pre-treated mantle cell lymphoma. J Clin Oncol. 2023;2023:101200JCO2300562.
   Google Scholar
• Kambhampati S, Ahmed N, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis by prior treatment. J Clin Oncol. 2023;41(16_suppl):7507–7507. doi:10.1200/JCO.2023.41.16_suppl.7507
   Web of Science ®Google Scholar
• Downing NS, Aminawung JA, Shah ND, et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA. 2014;311(4):368–377. doi:10.1001/jama.2013.282034
   PubMed Web of Science ®Google Scholar
• Tenhunen O, Lasch F, Schiel A, et al. Single‐arm clinical trials as pivotal evidence for cancer drug approval: a retrospective cohort study of centralized European marketing authorizations between 2010 and 2019. Clin Pharmacol Ther. 2020;108(3):653–660. doi:10.1002/cpt.1965
   PubMed Web of Science ®Google Scholar
• Goring S, Taylor A, Müller K, et al. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019;9(2):e024895. doi:10.1136/bmjopen-2018-024895
   PubMed Web of Science ®Google Scholar
• Hatswell AJ, Baio G, Berlin JA, et al. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014. BMJ Open. 2016;6(6):e011666. doi:10.1136/bmjopen-2016-011666
   PubMed Web of Science ®Google Scholar
• Purpura CA, Garry EM, Honig N, et al. The role of real-world evidence in FDA-approved new drug and biologics license applications. Clin Pharmacol Ther. 2022;111(1):135–144. doi:10.1002/cpt.2474
   PubMed Web of Science ®Google Scholar
• Ghione P, Palomba ML, Patel AR, et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022;140(8):851–860. doi:10.1182/blood.2021014375
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5(20):4149–4155. doi:10.1182/bloodadvances.2020003848
   PubMed Web of Science ®Google Scholar
• Salles G, Schuster SJ, Dreyling M, et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(22):5835–5843. doi:10.1182/bloodadvances.2022008150
   PubMed Web of Science ®Google Scholar
• Remiro-Azócar A, Heath A, Baio G. Parametric G-computation for compatible indirect treatment comparisons with limited individual patient data. Res Synth Methods. 2022;13(6):716–744. doi:10.1002/jrsm.1565
   PubMed Web of Science ®Google Scholar
• Daniel R, Zhang J, Farewell D. Making apples from oranges: comparing noncollapsible effect estimators and their standard errors after adjustment for different covariate sets. Biom J. 2021;63(3):528–557. doi:10.1002/bimj.201900297
   PubMed Web of Science ®Google Scholar